GlassScriptPhysician profile
Poonam Sidhu Dulai
NPI 1184737744
$9,423.24
in general payments reported to CMS, 2019-2025
50 companies · $1,314 in 2025
The $1,314 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,307 · 2020: $871 · 2021: $1,506 · 2022: $1,558 · 2023: $1,427 · 2024: $1,441 · 2025: $1,314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,133 · Education: $25.32 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,133.36 |
| Education | $25.32 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,205.11 | 2019-2025 | Vumerity, Plegridy |
| Acadia Pharmaceuticals INC | $750.39 | 2019-2025 | Nuplazid |
| Abbvie INC. | $649.37 | 2021-2025 | Qulipta, Vraylar |
| Eisai INC. | $447.54 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $425.01 | 2019-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Lilly USA, LLC | $410.40 | 2019-2025 | Kisunla, Amyvid, Reyvow |
| Ucb, INC. | $374.00 | 2019-2025 | Fintepla |
| Lundbeck LLC | $334.46 | 2019-2025 | Vyepti, Rexulti |
| Emd Serono, INC. | $332.42 | 2019-2024 | Mavenclad |
| Medtronic, INC. | $301.75 | 2021-2024 | Percept PC Brainsense |
| Arbor Pharmaceuticals, INC. | $295.29 | 2019-2021 | |
| Mdd US Operations, LLC | $215.38 | 2023-2025 | Gocovri, Gocovri |
| Almatica Pharma LLC | $212.30 | 2021-2023 | Gralise |
| Novartis Pharmaceuticals Corporation | $208.63 | 2019-2021 | |
| Genzyme Corporation | $202.31 | 2019-2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Poonam Dulai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.